Aarti Drugs — 360° view

Aarti Drugs, a company in the Pharmaceuticals industry, reported revenue of ₹826 crore and net profit of ₹83 crore for the September 2026 quarter.

Aarti Drugs (NSE: AARTIDRUGS) closed at ₹484.50 on 20 Nov 2026, up 8.4% over the past year. Its market capitalisation is ₹4,422 crore and it trades at 19.2 times earnings.

Share price
₹484.50 (20 Nov 2026)
Market cap
₹4,422 Cr (20 Nov 2026)
P/E
19.19 (20 Nov 2026)
Revenue
₹826 Cr (September 2026 quarter)
Net profit
₹83 Cr (September 2026 quarter)
ROCE
12.0% (FY26)
ROE
13.4% (FY26)
Book value
₹184 (FY26)
Dividend yield
0.41% (last 12 months to 20 Nov 2026)
52-week high / low
₹527.50 / ₹318.95 (20 Nov 2026)
1-year return
8.4% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: AARTIDRUGS

Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. It is exporting its API's and Speciality chemicals to over 100 countries across the globe.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.